Erschienen in:
13.06.2018 | Review
Screening and Surveillance for Barrett’s Esophagus: Is It Cost-Effective?
verfasst von:
John M. Inadomi, Nina Saxena
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 8/2018
Einloggen, um Zugang zu erhalten
Abstract
The cost-effectiveness of screening and surveillance for Barrett’s esophagus continues to evolve as the incidence of esophageal adenocarcinoma increases, biomarkers enhance the identification of individuals at highest risk for developing cancer, and endoscopic eradication of Barrett’s esophagus improves. Screening to detect Barrett’s esophagus may be cost-effective in selected high-risk groups based on age, race, sex and other factors such as symptoms of heartburn. Currently, endoscopic eradication therapy for Barrett’s esophagus and high-grade dysplasia is a cost-effective intervention, while endoscopic therapy for non-dysplastic Barrett’s esophagus is not a cost-effective strategy. As diagnosis of low-grade dysplasia improves, endoscopic eradication therapy may also prove to be a cost-effective intervention.